Skip to content

US · CVS · MEDICAL - HEALTHCARE PLANS

CVS Health Corp. (CVS) intrinsic value and stock valuation

$80.84as of 2026-11-21 · Mkt cap 122.11B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CVS Health Corp. DCF and intrinsic value

InvestorsCraft values CVS with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from CVS’s statements →

CVS Health Corp. Graham Number

Graham Number: $43.22d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Plans Woonsocket, RI 02895 cvshealth.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$402.1B+8.4% 5y CAGRd
20112025
Net income
$1.77B-24.4% 5y CAGRd
20112025
Free cash flow
$7.81B-10.3% 5y CAGRd
20112025
Total equity
$75.4B+1.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$402.1B$372.8B$357.8B$322.5B$292.1B
Operating income$10.4B$8.52B$13.7B$7.95B$13.3B
Net income$1.77B$4.61B$8.34B$4.31B$8B
EPSd$1.39M$3.66M$6.47M$3.26M$6.02M
Operating cash flow$10.6B$9.11B$13.4B$16.2B$18.3B
Capital expenditure-$-2.83B-$-2.78B-$-3.03B-$-2.73B-$-2.52B
Free cash flow$7.81B$6.33B$10.4B$13.5B$15.7B
Total assets$261.1B$253.2B$249.7B$228.3B$233B
Total debt$93.6B$82.9B$79.4B$70.7B$76B
Net debt$85.1B$74.3B$71.2B$57.8B$66.6B
Total equity$75.4B$75.7B$76.6B$71.8B$75.4B
Cash and short-term investments$10.7B$11B$11.5B$15.7B$12.5B
Income statement
20252024202320222021
Revenue$402.1B$372.8B$357.8B$322.5B$292.1B
Cost of revenue$346.7B$321.4B$303.3B$268B$240B
Gross profit$55.4B$51.4B$54.4B$54.5B$52.1B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$0.00$41.2B$0.00$0.00$0.00
Other expenses$45B$1.66B$40.7B$46.5B$38.8B
Operating expenses$45B$42.9B$40.7B$46.5B$38.8B
Cost and expenses$391.7B$364.3B$344B$314.5B$278.8B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$3.12B$2.96B$2.66B$2.29B$2.5B
Depreciation and amortization$4.61B$4.6B$4.37B$4.22B$4.49B
Ebitda$9.86B$13.7B$18.2B$12.3B$17.5B
Operating income$10.4B$8.52B$13.7B$7.95B$13.3B
Total other income/expenses, net-$-8.25B-$-2.37B-$-2.57B-$-2.12B-$-2.77B
Income before tax$2.14B$6.15B$11.2B$5.84B$10.5B
Income tax expense$408M$1.56B$2.81B$1.51B$2.55B
Net income$1.77B$4.61B$8.34B$4.31B$8B
Weighted average shares outstanding$1.27B$1.26B$1.29B$1.31B$1.32B
Weighted average diluted shares outstanding$1.27B$1.26B$1.29B$1.32B$1.33B
Balance sheet
20252024202320222021
Cash and short-term investments$10.7B$11B$11.5B$15.7B$12.5B
Net receivables$39.8B$36.5B$35.2B$27.3B$24.4B
Inventory$19.2B$18.1B$18B$19.1B$17.8B
Total current assets$74.7B$68.6B$67.9B$65.6B$60B
Property, plant and equipment, net$28.1B$28.9B$30.4B$30.7B$32B
Goodwill and intangible assets$111B$118.6B$120.5B$103B$108.1B
Long-term investments$32.9B$28.9B$23B$21.1B$23B
Total non-current assets$186.4B$184.6B$181.9B$162.6B$173B
Total assets$261.1B$253.2B$249.7B$228.3B$233B
Accounts payable$59.4B$15.9B$14.9B$14.8B$12.5B
Short-term debt$5.81B$7.49B$4.71B$3.46B$5.85B
Deferred revenue$62M$0.00$0.00$0.00$0.00
Total current liabilities$88.7B$84.6B$79.2B$69.4B$67.8B
Long-term debt$87.8B$75.4B$74.7B$67.3B$70.1B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$97B$92.9B$93.9B$87.1B$89.8B
Capital lease obligations$14.9B$16.7B$17.8B$18.5B$19.8B
Total liabilities$185.7B$177.5B$173.1B$156.5B$157.6B
Common stock$18M$18M$49B$48.2B$47.4B
Retained earnings$61.2B$62.8B$61.6B$56.4B$54.9B
Accumulated other comprehensive income (loss)$406M-$-120M-$-297M-$-1.26B$965M
Total equity$75.4B$75.7B$76.6B$71.8B$75.4B
Total investments$35B$31.3B$26.3B$23.9B$26.1B
Total debt$93.6B$82.9B$79.4B$70.7B$76B
Net debt$85.1B$74.3B$71.2B$57.8B$66.6B
Cash flow statement
20252024202320222021
Net income$1.73B$4.59B$8.37B$4.33B$7.99B
Depreciation and amortization$4.61B$4.6B$4.37B$4.22B$4.49B
Stock-based compensation$535M$540M$588M$447M$484M
Change in working capital-$-1.47B$109M$15M$6.82B$3.86B
Accounts receivable-$-3.5B-$-1.3B-$-6.26B-$-2.97B-$-2.7B
Inventory-$-1.27B-$-102M$1.23B-$-1.44B$735M
Accounts payable$3.86B$2.34B$3.62B$4.26B$2.9B
Net cash provided by operating activities$10.6B$9.11B$13.4B$16.2B$18.3B
Investments in property, plant and equipment-$-2.83B-$-2.78B-$-3.03B-$-2.73B-$-2.52B
Acquisitions, net-$-436M-$-95M-$-16.61B-$-1.39B-$-146M
Net cash used for investing activities-$-5.87B-$-7.61B-$-20.89B-$-5.05B-$-5.26B
Common stock issued$394M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00-$-3.02B-$-2.01B-$-3.5B$0.00
Dividends paid-$-3.4B-$-3.37B-$-3.13B-$-2.91B-$-2.63B
Net cash used for financing activities-$-4.94B-$-1.14B$2.68B-$-10.52B-$-11.36B
Net change in cash-$-172M$359M-$-4.78B$614M$1.65B
Cash at end of period$8.71B$8.88B$8.53B$13.3B$12.7B
Operating cash flow$10.6B$9.11B$13.4B$16.2B$18.3B
Capital expenditure-$-2.83B-$-2.78B-$-3.03B-$-2.73B-$-2.52B
Free cash flow$7.81B$6.33B$10.4B$13.5B$15.7B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CVS Health Corp.

        CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

        CEO
        J. David Joyner
        Employees
        259.5K
        Beta
        0.60

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of CVS Health Corp. (CVS)?

        CVS Health Corp. (CVS) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CVS undervalued?

        CVS trades at a price of $80.84 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.